Advanced Thyroid Cancer: Sacituzumab Govitecan Study

We are testing a new drug for patients with advanced differentiated and anaplastic thyroid neoplasms. The goal is to see if it can effectively control the disease and improve patient outcomes.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Trodelvy
Trodelvy is a cancer medicine used to treat certain advanced or metastatic breast and bladder cancers.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Sacituzumab Govitecan
Sacituzumab govitecan is an antibody-based cancer treatment that targets tumor cells and delivers a cell-killing agent to shrink certain advanced cancers.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Vall D'hebron Institut De Recerca
Oncología
Barcelona, Spain
Hospital Universitario La Paz
Oncología
Chamartín, Spain
MD Anderson Cancer Center
Oncología
Chamartín, Spain

Sponsor: Grupo Espanol De Tumores Neuroendocrinos
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.